Geno J. Germano Buys 3,250 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano bought 3,250 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average cost of $5.30 per share, with a total value of $17,225.00. Following the completion of the transaction, the director now owns 11,057 shares in the company, valued at approximately $58,602.10. This trade represents a 41.63 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $4.70 on Friday. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a fifty-two week low of $3.61 and a fifty-two week high of $15.97. The firm’s fifty day simple moving average is $5.11 and its 200-day simple moving average is $6.55. The stock has a market cap of $36.05 million, a PE ratio of 78.35 and a beta of 1.59.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Wednesday, March 26th. The company reported ($3.20) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($1.11). Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%. The company had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.28 million. Analysts expect that Precision BioSciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DTIL. BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Friday.

Hedge Funds Weigh In On Precision BioSciences

Several hedge funds have recently bought and sold shares of DTIL. Lynx1 Capital Management LP acquired a new stake in Precision BioSciences in the fourth quarter valued at $2,919,000. Janus Henderson Group PLC grew its stake in Precision BioSciences by 10.9% in the 3rd quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after acquiring an additional 68,943 shares during the last quarter. Citadel Advisors LLC increased its holdings in Precision BioSciences by 58.0% during the 4th quarter. Citadel Advisors LLC now owns 153,675 shares of the company’s stock valued at $586,000 after acquiring an additional 56,400 shares in the last quarter. Moloney Securities Asset Management LLC raised its position in Precision BioSciences by 177.0% during the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock worth $335,000 after acquiring an additional 56,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Precision BioSciences in the fourth quarter valued at about $211,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.